Investigation of Polypharmacy and Potential Drug-Drug Interactions in Prescriptions of Patients Hospitalized in Intensive Care Units: Retrospective Cross-Sectional Study

dc.contributor.authorKubat, Havva
dc.contributor.authorKarabacak, Elif
dc.date.accessioned2026-07-01T11:36:36Z
dc.date.available2026-07-01T11:36:36Z
dc.date.issued2026
dc.departmentDüzce Üniversitesi
dc.description.abstractObjective: Drug-drug interactions (DDIs) can reduce treatment efficacy or cause toxicity. This study aimed to evaluate the frequency of polypharmacy and potential DDIs in intensive care units (ICUs). Material and Methods: Prescriptions from tertiary ICUs over a one-month period were retrospectively analyzed for polypharmacy and DDIs. Potential DDIs were identified using the Drugs.com interaction checker. Results: A mean of 8.1 drugs were prescribed per patient. DDI risk was detected in 77% of patients. Polypharmacy was observed in 88.7% of patients, with a significantly higher mean number of drugs in this group (8.9±2.8 vs. 4.1±2.2; p<0.001). The mean number of potential DDIs per patient was 3.7 times higher in the polypharmacy group (2.46±3.02 vs. 0.66±1.04; p<0.001), and the odds of at least one interaction were 10.8 times higher (OR: 10.83; 95% CI: 5.24–22.4). A strong positive correlation was found between the number of drugs and DDI risk (r=0.71; p<0.001). Moderate interactions were most common, while minor interactions were least frequent. The drugs most frequently involved in potential DDIs were furosemide, tramadol, phenytoin, dexamethasone, pantoprazole, and enoxaparin. The most common potential DDI was between pantoprazole and furosemide. Potential DDIs most frequently affected the cardiovascular system, followed by the central nervous, musculoskeletal, electrolyte balance, renal, and gastrointestinal systems. Clinical manifestations included QT prolongation, convulsions, muscle cramps, hypomagnesemia, and bleeding. Conclusion: Polypharmacy significantly increases the risk of DDIs. The use of DDI screening programs in ICUs with high rates of polypharmacy may improve clinical outcomes. © 2026 by Türkiye Klinikleri.
dc.identifier.doi10.5336/medsci.2025-113745
dc.identifier.endpage88
dc.identifier.issn1300-0292
dc.identifier.issue1
dc.identifier.scopus2-s2.0-105032765275
dc.identifier.scopusqualityQ4
dc.identifier.startpage83
dc.identifier.urihttps://doi.org/10.5336/medsci.2025-113745
dc.identifier.urihttps://hdl.handle.net/20.500.12684/23127
dc.identifier.volume46
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherTurkiye Klinikleri
dc.relation.ispartofTurkiye Klinikleri Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260623
dc.subjectdrug interaction checker/tool
dc.subjectDrug interactions
dc.subjectintensive care
dc.subjectpolypharmacy
dc.titleInvestigation of Polypharmacy and Potential Drug-Drug Interactions in Prescriptions of Patients Hospitalized in Intensive Care Units: Retrospective Cross-Sectional Study
dc.title.alternativeYoğun Bakım Ünitelerinde Yatan Hastaların Reçetelerinde Polifarmasi ve Olası İlaç-İlaç Etkileşimlerinin Araştırılması: Retrospektif Kesitsel Araştırma]
dc.typeArticle

Dosyalar